Clinical Trials

398 enrolled

Biliary Tract Neoplasms

NCT07582315 2026-05-22

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

538 enrolled

Biliary Tract Neoplasms

NCT07580339 2026-05-12

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

30 enrolled

Rectal Neoplasms

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07570914 2026-05-06

Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases

28 enrolled

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT07551778 2026-04-27

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

20 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07549906 2026-04-24

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

45 enrolled

Colonic Neoplasms

NCT07551479 2026-04-24

TORCH-STAR

Phase 1/2 Not yet recruiting

612 enrolled

Spinocerebellar Degenerations

NCT07494448 2026-04-23

JAZMINE

24 enrolled

Breast Neoplasms

NCT06622057 2026-04-14

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

195 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

44 enrolled

Rectal Cancer Patients

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT07503639 2026-03-31

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

134 enrolled

Locally Advanced Colorectal Cancer

NCT07486687 2026-03-20

PLANET

1,000 enrolled

Phase 4 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07483060 2026-03-19

NG-ST

90 enrolled

Rectal Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Phase 1/2 Not yet recruiting

Locally Advanced Rectal Cancer

NCT07456852 2026-03-09

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

60 enrolled

Gastrointestinal Neoplasms

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

218 enrolled

Nasopharyngeal Carcinoma

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

100 enrolled

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

400 enrolled

Breast Neoplasms, Recurrence

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

120 enrolled

Carcinoma, Hepatocellular

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

752 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Phase 4 Not yet recruiting

Breast Neoplasms

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Colorectal Neoplasms

NCT07340567 2026-01-14

CIRCULATEIII

2,450 enrolled

Colorectal Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

HER2-positive Gastric Cancer

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

138 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Nasopharyngeal Carcinoma

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT07296666 2025-12-22

Adjuvant Chemotherapy for BTC Based on 3D-PTA

98 enrolled

Cholangiocarcinoma

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT07254962 2025-11-28

CAPTURE

75 enrolled

Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

737 enrolled

Esophageal Squamous Cell Carcinoma

NCT07243938 2025-11-24

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

70 enrolled

Colorectal Neoplasms

NCT07243951 2025-11-24

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

75 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Liver Neoplasms

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Nasopharyngeal Cancinoma (NPC)

NCT07233850 2025-11-18

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

300 enrolled

Esophageal Neoplasms, Colorectal Neoplasms

NCT07151872 2025-09-03

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

120 enrolled

CLDN18.2-positive Advanced Biliary Tract Cancer

NCT07134101 2025-08-29

SMARTi-RC01

138 enrolled

Disease, Colorectal Neoplasms

NCT07132008 2025-08-20

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

94 enrolled

Colonic Neoplasms

NCT07025239 2025-06-17

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

430 enrolled

Colorectal Neoplasms

NCT07019337 2025-06-13

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

100 enrolled

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

440 enrolled

Breast Neoplasms

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

153 enrolled